FOMX - Foamix Pharmaceuticals Ltd.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
5.19
-0.55 (-9.58%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close5.74
Open5.74
Bid0.00 x 900
Ask0.00 x 42300
Day's Range5.03 - 5.74
52 Week Range4.40 - 7.60
Volume2,514,167
Avg. Volume594,334
Market Cap281.556M
Beta2.96
PE Ratio (TTM)N/A
EPS (TTM)-2.09
Earnings DateNov 12, 2018 - Nov 16, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.50
Trade prices are not sourced from all markets
  • GlobeNewswire17 hours ago

    Foamix Announces Closing of its Follow-on Offering of Ordinary Shares and Full Exercise of its Option by the Underwriters

    Foamix Pharmaceuticals Ltd. (“Foamix”) (FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today announced the closing of its previously announced underwritten public offering of 13,420,500 ordinary shares at a price to the public of $6.00 per share. This included the 30-day option to purchase up to an additional 1,750,500 ordinary shares from Foamix on the same terms and conditions, which was exercised in full by the underwriters. All of the ordinary shares sold in the offering were offered by Foamix.

  • GlobeNewswire5 days ago

    Foamix Announces Pricing of its Follow-on Offering of Ordinary Shares

    Foamix Pharmaceuticals Ltd. (“Foamix”) (FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary, topical therapies to address unmet needs in dermatology, today announced the pricing of an underwritten public offering of 11,670,000 ordinary shares at a price to the public of $6.00 per share. All of the ordinary shares to be sold in the offering will be offered by Foamix. In addition, Foamix has granted the underwriters a 30-day option to purchase up to an additional 1,750,500 ordinary shares on the same terms and conditions.

  • ACCESSWIRE6 days ago

    Today's Research Reports on Trending Tickers: Progenics Pharmaceuticals and Foamix Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / September 13, 2018 / U.S. markets were mixed on Wednesday as technology shares declined, dragging the Nasdaq into the red. The Dow Jones Industrial Average climbed 0.11 percent ...

  • GlobeNewswire6 days ago

    Foamix Announces Proposed Follow-on Offering of Ordinary Shares

    Foamix Pharmaceuticals Ltd. (“Foamix”) (FOMX), a clinical-stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced that it intends to offer and sell, subject to market conditions, $70,000,000 of its ordinary shares in an underwritten public offering. All of the ordinary shares to be sold in the offering will be offered by Foamix. Foamix also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the ordinary shares sold in the public offering on the same terms and conditions.

  • ACCESSWIRE7 days ago

    Cannabis and Biotech Stock that could Explode

    HENDERSON, NV / ACCESSWIRE / September 12, 2018 / One company that has been explosive in the past is Propanc Biopharma, Inc. (PPCB). PPCB is a very interesting biotech play. PPCB is a clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors, such as pancreatic, ovarian and colorectal cancers.

  • Foamix's Acne Candidate Succeeds in Study, Shares Rally
    Zacks7 days ago

    Foamix's Acne Candidate Succeeds in Study, Shares Rally

    Foamix's (FOMX) acne candidate, FMX101, meets co-primary endpoints in the third phase III study, FX2017-22.

  • MarketWatch7 days ago

    Foamix stock surges 30% on positive late-stage results for acne medication

    Foamix Pharmaceuticals Ltd. shares surged 30% in Wednesday premarket trade after the company reported positive late-stage trial results for its topical acne medication, FMX101. The phase 3 trial met both co-primary endpoints after 12 weeks of daily treatment with the medication. FMX101 is a topical foam made of the antibiotic minocycline and, if approved, would be the first such topical product available in the U.S., according to the company. The trial enrolled 1,507 individuals with moderate-to-severe acne across the U.S. The medication "appeared to be generally safe and well-tolerated," the company said, with a viral upper respiratory tract infection, in 6.5% of trial participants, being the most common safety problem reported. Five participants total dropped out of the study due to safety issues. Foamix said it plans to share further data from the recent study over the course of the year. Company shares have surged 13.9% to $5.92 over the last three months, compared with a 3.6% rise in the S&P 500 and a 2.6% rise in the Dow Jones Industrial Average .

  • MarketWatch7 days ago

    Foamix's stock rockets after successful trial results for acne treatment

    Shares of Foamix Pharmaceuticals Ltd. soared 29% toward an 18-month high in premarket trade Wednesday, after the pharmaceutical company said a phase 3 study of its moderate-to-severe acne treatment met both co-primary endpoints. The safety profile was consistent with that determined from two prior phase 3 studies. "This is the most significant milestone to date for Foamix and brings us closer to helping patients who struggle with the physical and psycho-social effects of acne," said Chief Executive David Domzalski, in a release out late Tuesday. "If approved, we believe FMX101 would be the first topical minocycline product available for patients in the United States." The stock had lost 1.5% year to date through Tuesday, while the S&P 500 had gained 8.0%.

  • Benzinga7 days ago

    The Daily Biotech Pulse: Foamix Jumps on Data, Positive Results for Galapagos-Gilead's Rheumatoid Arthritis Drug, Bausch Health Trims Debt

    Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 11.) BioSpecifics Technologies Corp. (NASDAQ: BSTC ) Genomic ...

  • Reuters7 days ago

    Foamix acne drug meets main goals in late-stage trial, shares surge

    Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading. FMX101, a topical minocycline foam, showed significant reduction in the number of inflammatory lesions in the trial which enrolled 1,507 patients, the company said. "If approved, we believe FMX101 would be the first topical minocycline product available for patients in the United States," Chief Executive David Domzalski said in a statement.

  • GlobeNewswire7 days ago

    Foamix Announces Positive Topline Results from Third Phase 3 Trial (Study FX2017-22) Evaluating FMX101 Topical Minocycline Foam for Moderate-to-Severe Acne

    Foamix Pharmaceuticals Ltd. (FOMX), (“Foamix”), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical therapies to address unmet needs in dermatology, today announced the topline results of its third Phase 3 clinical trial (FX2017-22) of FMX101 for the treatment of moderate-to-severe acne. The study met both co-primary endpoints of (1) absolute change from baseline in inflammatory lesion count at Week 12, and (2) Investigator Global Assessment (“IGA”) treatment success at Week 12, defined as an IGA score of 0 or 1, and at least a 2-grade improvement (decrease) from baseline. “We are extremely pleased with the topline results of this confirmatory Phase 3 trial.

  • Did An Insider Sell Their Shares In Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)?
    Simply Wall St.12 days ago

    Did An Insider Sell Their Shares In Foamix Pharmaceuticals Ltd (NASDAQ:FOMX)?

    Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the UnitedRead More...

  • Implied Volatility Surging for Foamix Pharmaceuticals (FOMX) Stock Options
    Zacks29 days ago

    Implied Volatility Surging for Foamix Pharmaceuticals (FOMX) Stock Options

    Investors in Foamix Pharmaceuticals (FOMX) need to pay close attention to the stock based on moves in the options market lately.

  • Foamix (FOMX) Reports Q2 Loss, Lags Revenue Estimates
    Zackslast month

    Foamix (FOMX) Reports Q2 Loss, Lags Revenue Estimates

    Foamix (FOMX) delivered earnings and revenue surprises of 22.03% and -12.36%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Presslast month

    Foamix: 2Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had a loss of 46 cents. The acne treatment developer posted revenue of $964,000 in the period. Foamix shares have decreased 4 percent since ...

  • GlobeNewswirelast month

    Foamix Reports Second Quarter 2018 Financial Results and Provides Corporate Update

    REHOVOT, Israel, Aug. 08, 2018-- Foamix Pharmaceuticals Ltd., a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs ...

  • GlobeNewswire2 months ago

    Foamix Pharmaceuticals to Announce Second Quarter Financial Results on August 8

    REHOVOT, Israel, and BRIDGEWATER, N.J., Aug. 01, 2018-- Foamix Pharmaceuticals Ltd.,, a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams ...

  • GlobeNewswire3 months ago

    CORRECTING and REPLACING -- Foamix Announces Dosing of Last Patient in Phase 3 Rosacea Studies for Minocycline Foam FMX103

    In a release issued under the same headline earlier today by Foamix (FOMX), please note that in the second paragraph of the release, the top-line data announcement should be in the third quarter, not early in the fourth, as previously stated. REHOVOT, Israel, and BRIDGEWATER, N.J., June 27, 2018 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (FOMX), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it has completed patient enrollment and has dosed the last patient in its two Phase 3 clinical studies (FX2016-11 and FX2016-12) evaluating the safety and efficacy of FMX103, topical minocycline foam 1.5%, for the treatment of rosacea.  The two Phase 3 pivotal studies are being run simultaneously, and the Company currently anticipates reporting top-line results early in the fourth quarter of this year.

  • Why Galmed Pharmaceuticals Stock Rose 151% on June 12
    Market Realist3 months ago

    Why Galmed Pharmaceuticals Stock Rose 151% on June 12

    Galmed Pharmaceuticals (GLMD) stock rose 151.3% on June 12. Galmed stock rose after the company announced top-line results from the global 52-week phase 2b ARREST trial. The company is conducting the phase 2b ARREST trial to evaluate the safety and efficacy of its Aramchol for the treatment of individuals with non-alcoholic steatohepatitis (or NASH).

  • May Best Growth Stocks
    Simply Wall St.4 months ago

    May Best Growth Stocks

    Most investors find it challenging to find companies with prospective double-digit growth rates that are also financially robust. These hidden gems also add meaningful upside to a portfolio, should theRead More...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of FOMX earnings conference call or presentation 9-May-18 12:30pm GMT

    Q1 2018 Foamix Pharmaceuticals Ltd Earnings Call

  • With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?
    Simply Wall St.4 months ago

    With A -124.01% Earnings Drop, Did Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) Really Underperform?

    For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...

  • Associated Press4 months ago

    Foamix: 1Q Earnings Snapshot

    On a per-share basis, the Rehovot, Israel-based company said it had a loss of 69 cents. The acne treatment developer posted revenue of $906,000 in the period. Foamix shares have decreased 15 percent since ...